Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term lumacaftor + ivacaftor in cystic fibrosis (F508del homozygous, age ≥2 years)
2019-003112-31Phase 3
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lumacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability (AEs and SAEs).
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2019-003112-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003112-31.